IS4838A - Indól afleiður nytsamlegar sem innanþekjuviðtaka mótlyf - Google Patents

Indól afleiður nytsamlegar sem innanþekjuviðtaka mótlyf

Info

Publication number
IS4838A
IS4838A IS4838A IS4838A IS4838A IS 4838 A IS4838 A IS 4838A IS 4838 A IS4838 A IS 4838A IS 4838 A IS4838 A IS 4838A IS 4838 A IS4838 A IS 4838A
Authority
IS
Iceland
Prior art keywords
receptor antagonists
indole derivatives
derivatives useful
epithelial receptor
epithelial
Prior art date
Application number
IS4838A
Other languages
English (en)
Other versions
IS1856B (is
Inventor
James Rawson David
Neil Dack Kevin
Peter Dickinson Roger
James Kim
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of IS4838A publication Critical patent/IS4838A/is
Publication of IS1856B publication Critical patent/IS1856B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
IS4838A 1996-05-09 1998-08-28 Indól afleiður nytsamlegar sem innanþekjuviðtaka mótlyf IS1856B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9609641.7A GB9609641D0 (en) 1996-05-09 1996-05-09 Compounds useful in therapy
PCT/EP1997/001882 WO1997043260A1 (en) 1996-05-09 1997-04-11 Indole derivatives useful as endothelin receptor antagonists

Publications (2)

Publication Number Publication Date
IS4838A true IS4838A (is) 1998-08-28
IS1856B IS1856B (is) 2003-02-21

Family

ID=10793387

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4838A IS1856B (is) 1996-05-09 1998-08-28 Indól afleiður nytsamlegar sem innanþekjuviðtaka mótlyf

Country Status (42)

Country Link
US (4) US6017945A (is)
EP (1) EP0901470B1 (is)
JP (1) JP3245179B2 (is)
KR (1) KR100331217B1 (is)
CN (1) CN1124262C (is)
AP (1) AP830A (is)
AR (1) AR007030A1 (is)
AT (1) ATE263151T1 (is)
AU (1) AU717849B2 (is)
BG (1) BG102873A (is)
BR (1) BR9709072A (is)
CA (1) CA2253876A1 (is)
CO (1) CO4650036A1 (is)
CZ (1) CZ292928B6 (is)
DE (1) DE69728392T2 (is)
DK (1) DK0901470T3 (is)
DZ (1) DZ2227A1 (is)
EA (1) EA001471B1 (is)
ES (1) ES2218675T3 (is)
GB (1) GB9609641D0 (is)
HN (1) HN1997000058A (is)
HR (1) HRP970249B1 (is)
HU (1) HUP9901245A3 (is)
ID (1) ID16878A (is)
IL (1) IL125903A0 (is)
IS (1) IS1856B (is)
MA (1) MA26428A1 (is)
NO (1) NO312547B1 (is)
NZ (1) NZ332640A (is)
OA (1) OA10896A (is)
PE (1) PE65098A1 (is)
PL (1) PL329725A1 (is)
PT (1) PT901470E (is)
SI (1) SI0901470T1 (is)
SK (1) SK150398A3 (is)
TN (1) TNSN97078A1 (is)
TR (1) TR199802269T2 (is)
TW (1) TW491838B (is)
UA (1) UA50767C2 (is)
UY (1) UY24546A1 (is)
WO (1) WO1997043260A1 (is)
ZA (1) ZA973963B (is)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9722287D0 (en) 1997-10-22 1997-12-17 Pfizer Ltd Compounds useful in therapy
PT1154774E (pt) 1999-02-10 2005-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de angiogenese
GB0016162D0 (en) * 2000-06-30 2000-08-23 Cancer Res Campaign Tech Indole-3-acetic acid derivatives
US20050203166A1 (en) * 2000-06-30 2005-09-15 Cancer Research Technology Limited Indole-3-acetic acid derivatives
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
US7074817B2 (en) 2001-06-20 2006-07-11 Wyeth Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
AR037097A1 (es) 2001-10-05 2004-10-20 Novartis Ag Compuestos acilsulfonamidas, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento
UA80453C2 (en) 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
EP1569900B1 (en) 2002-12-10 2006-06-28 Wyeth Substituted 3-carbonyl-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
DE60324183D1 (en) 2002-12-10 2008-11-27 Wyeth Corp Aryl-, aryloxy- und alkyloxysubstituierte 1h-indol-3-yl-glyoxylsäurederivateals inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1)
CA2509222A1 (en) 2002-12-10 2004-06-24 Wyeth Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
CA2509170A1 (en) 2002-12-10 2004-06-24 Wyeth Substituted 3-alkyl and 3-arylalkyl 1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
CN1742007A (zh) * 2003-01-22 2006-03-01 伊莱利利公司 甾族激素核受体的吲哚衍生物调控剂
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7332521B2 (en) 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7534894B2 (en) 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
US7342039B2 (en) 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7420083B2 (en) 2003-09-25 2008-09-02 Wyeth Substituted aryloximes
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7582773B2 (en) 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7141592B2 (en) 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
JP2005109006A (ja) * 2003-09-29 2005-04-21 Tdk Corp 高電圧貫通型コンデンサ及びマグネトロン
HN2004000536A (es) 2003-12-16 2009-02-18 Wyeth Corp Un procediemiento de sintesis para la alquilacion reductiva de la posicon c-3 de indoles
AU2005277137A1 (en) 2004-08-23 2006-03-02 Wyeth Pyrrolo-naphthyl acids as PAI-1 inhibitors
CN101044127A (zh) 2004-08-23 2007-09-26 惠氏公司 用作纤溶酶原激活剂抑制剂－1的噻唑基－萘基酸
WO2006023865A1 (en) 2004-08-23 2006-03-02 Wyeth Oxazolo-naphthyl acids as plaminogen activator inhibtor type-1 (pai-1) modulators useful in the treatment of thrombosis and cardiovascular diseases
BRPI0614340A2 (pt) 2005-08-17 2011-04-12 Wyeth Corp indóis substituìdos e métodos de seu uso
SG174050A1 (en) * 2006-04-13 2011-09-29 Actelion Pharmaceuticals Ltd Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
DE102008030206A1 (de) 2008-06-25 2009-12-31 Bayer Schering Pharma Aktiengesellschaft 3-Cyanoalky- und 3-Hydroxyalkyl-Indole und ihre Verwendung
DE102008030207A1 (de) 2008-06-25 2009-12-31 Bayer Schering Pharma Aktiengesellschaft Substituierte 7-Sulfanylmethyl-, 7-Sulfinylmethyl- und 7-Sulfonylmethyl-Indole und ihre Verwendung
EP3519816A4 (en) 2016-09-29 2020-05-06 The Regents of the University of California CONNECTIONS FOR INCREASING NEURONAL PLASTICITY
CN106674065A (zh) * 2016-12-07 2017-05-17 贵州大学 一种5‑卤代‑2‑烷氧基‑4‑甲苯磺酰氯制备方法
GB201817038D0 (en) * 2018-10-19 2018-12-05 Inflazome Ltd Novel processes
KR102946120B1 (ko) 2019-02-27 2026-03-30 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클
IL313455A (en) 2021-12-15 2024-08-01 Delix Therapeutics Inc Phenoxy and benzyloxy modified psychroplastogens and their uses
CN117263832B (zh) * 2023-08-18 2026-02-03 辽宁龙田化工科技有限公司 一种2-氯-4-甲磺酰基苯甲酸合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL297889A (is) * 1962-09-14
DE1950346B2 (de) * 1968-10-08 1973-06-28 Sumitomo Chemical Co 2-indolylessigsaeureverbindungen und diese verbindungen enthaltende arzneipraeparate
US4397079A (en) * 1981-03-30 1983-08-09 International Business Machines Corp. Process for improving the yield of integrated devices including Schottky barrier diodes
US5245046A (en) * 1988-11-14 1993-09-14 The Upjohn Company α-amino-indole-3-acetic acids useful as anti-diabetic, anti-obesity and anti-atherosclerotic agents
US5468898A (en) 1990-09-10 1995-11-21 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted naphthylene compounds exhibiting selective leukotriene B4 antagonist activity
ZA939516B (en) * 1992-12-22 1994-06-06 Smithkline Beecham Corp Endothelin receptor antagonists
PT617001E (pt) * 1993-03-19 2000-06-30 Merck & Co Inc Derivados do acido fenoxifenilacetico
GB9317096D0 (en) * 1993-08-17 1993-09-29 Pfizer Ltd Indoles

Also Published As

Publication number Publication date
US6384070B2 (en) 2002-05-07
AU2697897A (en) 1997-12-05
NO312547B1 (no) 2002-05-27
CN1216531A (zh) 1999-05-12
KR100331217B1 (ko) 2002-05-09
BG102873A (en) 1999-11-30
US6306852B1 (en) 2001-10-23
JP3245179B2 (ja) 2002-01-07
MA26428A1 (fr) 2004-12-20
BR9709072A (pt) 1999-08-03
OA10896A (en) 2001-10-11
NO985225L (no) 1998-11-09
EP0901470A1 (en) 1999-03-17
HUP9901245A3 (en) 2002-01-28
ID16878A (id) 1997-11-20
US6017945A (en) 2000-01-25
KR20000010879A (ko) 2000-02-25
CO4650036A1 (es) 1998-09-03
TW491838B (en) 2002-06-21
PE65098A1 (es) 1998-10-29
NO985225D0 (no) 1998-11-09
WO1997043260A1 (en) 1997-11-20
CZ358298A3 (cs) 1999-08-11
HRP970249A2 (en) 1998-06-30
IS1856B (is) 2003-02-21
ZA973963B (en) 1998-11-09
DE69728392T2 (de) 2005-01-13
SI0901470T1 (en) 2004-08-31
CA2253876A1 (en) 1997-11-20
AU717849B2 (en) 2000-04-06
UY24546A1 (es) 2000-09-29
CN1124262C (zh) 2003-10-15
HRP970249B1 (en) 2003-06-30
EA001471B1 (ru) 2001-04-23
DK0901470T3 (da) 2004-07-12
JPH11508285A (ja) 1999-07-21
AP830A (en) 2000-05-03
HUP9901245A2 (hu) 1999-08-30
ATE263151T1 (de) 2004-04-15
US6136843A (en) 2000-10-24
NZ332640A (en) 2001-03-30
HK1019149A1 (en) 2000-01-14
CZ292928B6 (cs) 2004-01-14
ES2218675T3 (es) 2004-11-16
TNSN97078A1 (fr) 2005-03-15
AP9700982A0 (en) 1997-07-31
US20010014677A1 (en) 2001-08-16
HN1997000058A (es) 1997-06-26
UA50767C2 (uk) 2002-11-15
PL329725A1 (en) 1999-04-12
EA199800908A1 (ru) 1999-06-24
DZ2227A1 (fr) 2002-12-25
IL125903A0 (en) 1999-04-11
SK150398A3 (en) 1999-03-12
EP0901470B1 (en) 2004-03-31
AR007030A1 (es) 1999-10-13
GB9609641D0 (en) 1996-07-10
PT901470E (pt) 2004-07-30
TR199802269T2 (xx) 2001-12-21
DE69728392D1 (de) 2004-05-06

Similar Documents

Publication Publication Date Title
IS4838A (is) Indól afleiður nytsamlegar sem innanþekjuviðtaka mótlyf
FI973205L (fi) Indolijohdannaisia 5-HT-reseptoriantagonisteina
DE69734833D1 (de) Vitronektin rezeptor antagonisten
IS5706A (is) Adenosín A3 viðtakastillar
DE69921351D1 (de) 4-aroyl-piperidin-ccr-3 rezeptor antagonisten iii
FI961628A7 (fi) Indolijohdannaisia NMDA-antagonisteina
EP0929218A4 (en) P2Y RECEPTOR ANTAGONISTS
NO985970D0 (no) Indolinderivater anvendelige som 5_HT-2C-reseptor-antagonister
NO985972L (no) Indolinderivater anvendelige som 5-HT-2C reseptorantagonister
AU3611099A (en) Oxindole derivatives used as neurokinin receptor antagonists
AU2943899A (en) Indole derivatives as 5-ht2a receptor antagonists
SI0912556T1 (en) Indoline derivatives useful as 5-ht-2c receptor antagonists
FI963463L (fi) Indolijohdannaiset CCK-reseptoriantagonisteina
EP0957908A4 (en) FIBRINOGEN RECEPTOR ANTAGONISTS
HK1019747A (en) Indoline derivatives useful as 5-ht-2c receptor antagonists